Type 2 diabetes

News

Eli Lilly has added another arrow to the quiver of new diabetes and obesity drug retatrutide, outperforming Novo's Ozempic in a head-to-head trial.

News

Eli Lilly's oral GLP-1 Foundayo has been recommended for weight reduction and type 2 diabetes in the EU, plus other CHMP decisions.

News

As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.

News

Eli Lilly's bid to dominate the next generation of weight-loss therapies has been strengthened by data on its new combination therapy EloraTZP.

News

Eli Lilly has revealed more data with its triple G agonist retatrutide, boosting its credentials as the next big thing in cardiometabolic diseases.

News

The FDA has approved Eli Lilly's once-weekly basal insulin product Onswik, setting up a market tussle with Novo's recently launched Awiqli.